Cytosorbents Corporation (CTSO) NASDAQ
0.48
+0.0121(+2.59%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.48
+0.0121(+2.59%)
Currency In USD
| Previous Close | 0.47 |
| Open | 0.48 |
| Day High | 0.49 |
| Day Low | 0.45 |
| 52-Week High | 1.39 |
| 52-Week Low | 0.44 |
| Volume | 30,662 |
| Average Volume | 93,074 |
| Market Cap | 30.14M |
| PE | -2.53 |
| EPS | -0.19 |
| Moving Average 50 Days | 0.58 |
| Moving Average 200 Days | 0.73 |
| Change | 0.01 |
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller
GlobeNewswire Inc.
Mar 04, 2025 12:00 PM GMT
The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing applications in 2025PRINCETON, N.J., March 04, 202
CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
GlobeNewswire Inc.
Feb 26, 2025 12:00 PM GMT
PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter
CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants
GlobeNewswire Inc.
Feb 25, 2025 12:00 PM GMT
1,417,208 Series A Right Warrants Exercised at $1.13 Per Share, Providing $1.6 Million in Aggregate Gross ProceedsPRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threaten